Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asymptomatic Infections Clear all
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

NCT04840199
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus, CMV
Interventions
Letermovir Oral Tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT00002260
View directory record Official record
Conditions
HIV Infections
Interventions
Alovudine
Drug
Lead sponsor
Lederle Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 4:09 AM EDT
Not yet recruiting Phase 2 Interventional

A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization

NCT07792915
View directory record Official record
Conditions
Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae, Asymptomatic Infections
Interventions
Resistant Potato Starch, Maltodextrin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Asymptomatic Bacteriuria Guideline Implementation Study

NCT01052545
View directory record Official record
Conditions
Infection Due to Indwelling Urinary Catheter, Asymptomatic Bacteriuria
Interventions
Audit-Feedback
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

NCT00464542
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)

NCT01335191
View directory record Official record
Conditions
HIV Infections
Interventions
TUTI-16 (1.0 mg), Placebo
Biological · Other
Lead sponsor
Thymon, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

NCT00001036
View directory record Official record
Conditions
HIV Infections
Interventions
Thymalfasin, Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Testing Pilot Study

NCT04843878
View directory record Official record
Conditions
Diagnostic Test, Routine, Coronavirus, Diagnoses Disease, Rapid Coronavirus Test
Interventions
COVID Detect
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections

NCT04495699
View directory record Official record
Conditions
Urinary Tract Infections, Kidney Stone
Interventions
None - observational
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Phoenix, Arizona • San Diego, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection

NCT00001000
View directory record Official record
Conditions
HIV Infections
Interventions
Ampligen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1990
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Not applicable Interventional

A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3

NCT00001064
View directory record Official record
Conditions
HIV Infections
Interventions
Allogenic Dendritic Cells
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

A Study of Anti-HIV Monoclonal Antibody KD-247

NCT00917813
View directory record Official record
Conditions
HIV Infections
Interventions
KD-247, Physiological saline
Drug
Lead sponsor
The Chemo-Sero-Therapeutic Research Institute
Industry
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
15
States / cities
Beverly Hills, California • Burbank, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)

NCT00002079
View directory record Official record
Conditions
HIV Infections
Interventions
Butyldeoxynojirimycin, Zidovudine
Drug
Lead sponsor
G D Searle
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
San Francisco, California • Tarzana, California • Miami Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Diagnostic for Detection of COVID-19 Infection

NCT04742569
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
ClinOne, Inc.
Industry
Eligibility
18 Years and older
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Greenwood Village, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection

NCT00000750
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 9 Months
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
41
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

NCT00001005
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients

NCT00002350
View directory record Official record
Conditions
HIV Infections
Interventions
APL 400-003
Biological
Lead sponsor
Apollon
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

NCT04452318
View directory record Official record
Conditions
Healthy Participants
Interventions
REGN10933 + REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Day and older
Enrollment
3,303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
132
States / cities
Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

NCT00002323
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection

NCT00002078
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-n3
Drug
Lead sponsor
Purdue Frederick
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

NCT00000667
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Not yet recruiting Not applicable Interventional

De-implementing PreOp Urine Testing

NCT07411209
View directory record Official record
Conditions
Urinary Tract Infection, Asymptomatic Bacteriuria
Interventions
Interventional Project Site Visit
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit

NCT04720235
View directory record Official record
Conditions
Covid19, Corona Virus Infection
Interventions
Lucira COVID-19 All-In-One test kit
Device
Lead sponsor
Lucira Health Inc
Industry
Eligibility
14 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Gatos, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

NCT00000977
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 17, 2026, 4:09 AM EDT